Stimulation of the immune system's ability to control and destroy tumors cont- ues to be the goal of cancer immune therapy; but the scope has rapidly expanded; approaches are constantly updated; new molecules are continually introduced; and immune mechanisms are becoming better understood. This book has no intention of covering every aspect of immune therapy but rather focuses on the novelty of cancer immune therapy in an attempt to give readers an opportunity to absorb the new aspects of immune therapy from a single source. In this regard, three areas were selected: cytokine immune therapy, cell-based immune therapy, and targeted immune therapy. In each of these three sections, only the novel aspects of immune therapy were described instead of attempting to cover any historical achievement. In the first section, Cytokine Immune Therapy, the IL12 family, IL18, IL21, IL24, IL28, and IL29 were emphasized in regard to the an- tumor function and application in treating tumors. Most of these selected cyt- ines were discovered in last 10 years. In the second section, Cell-based Immune Therapy, the focus was engineering potent immune regulatory or effector cells such as dendritic cells, T cells, and stem cells. Cell engineering design is primarily based on the increased understanding of the interaction of tumor antigen-presenting cells, antigen- specific effector cells, and the tumor microenvironment.
Targeted Cancer Immune Therapy
Fri frakt för privatpersoner! Skickas inom 1‑3 vardagar
- Författare: Joseph (EDT) Lustgarten Yan (EDT) Cui Shulin (EDT) Li
- Språk: Engelska
- Utgiven: 2009-09
- ISBN: 9781441901699
- Förlag: Springer-Verlag New York Inc.
- Upplaga: 1
- Antal sidor: 343
- Vikt: 612 gram